Tharakorn/iStock via Getty Images
MoonLake Immunotherapeutics (NASDAQ:MLTX) has licensed novel nanobody technology to address a couple of inflammatory diseases in major markets, taking on the burden of further developing and commercialising the technology. In theory, there might be an interesting value
If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab. We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4%. We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some inspiration. Give our no-strings-attached free trial a try to see if it's for you.
